CNX Therapeutics and Adalvo announce strategic agreement for commercialization of Nitrofurantoin

CNX Therapeutics Limited has announced an exclusive partnership with Adalvo to commercialise a prolonged release formulation of Nitrofurantoin, an antimicrobial medication used in the treatment of acute uncomplicated urinary tract infections (UTIs).

Nitrofurantoin PR, now available in the UK as the first generic version, offers healthcare providers a high-quality, cost-effective therapeutic alternative for treating UTIs.

CNX Therapeutics expects to expand the availability of Nitrofurantoin PR to additional European markets throughout 2025, further enhancing its commitment to delivering critical hospital products globally.

This acquisition strengthens CNX Therapeutics’ portfolio of products, marking a significant milestone in the company’s growth.

“We are very excited to be partnering with Adalvo to launch a prolonged release formulation of Nitrofurantoin in Europe”, said Guy Clark, CEO of CNX Therapeutics. “This partnership aligns with CNX’s strategy to provide innovative, high-quality products that meet the needs of healthcare providers to transform patient care. Our partnership with Adalvo has been key in bringing this important product to market, and we look forward to continuing our collaboration to expand access to essential medicines.”

“Nitrofurantoin is a unique and challenging product,” said Anil Okay, CEO of Adalvo. “This launch highlights Adalvo’s ability to navigate complex development and regulatory pathways while also delivering high-quality differentiated treatments to market. We are excited to bring this product to the UK market and remain dedicated to expanding access to high-quality treatments.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>